Yttrium 90-radiolabelled OTSA 101

Drug Profile

Yttrium 90-radiolabelled OTSA 101

Alternative Names: Frizzled homologue 10 antibodies - OncoTherapy Science; Frizzled-10 antibodies - OncoTherapy Science; Fz-10 antibodies - OncoTherapy Science; FZD10 monoclonal antibodies - OncoTherapy Science; hFz10 antibodies - OncoTherapy Science; OTSA 101 DTPA-90Y; OTSA101; TT641 pAb - OncoTherapy Science

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoTherapy Science
  • Developer Centre Leon Berard; OncoTherapy Science
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals; Radiosensitisers
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Synovial sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Synovial-sarcoma in France (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Synovial-sarcoma in Japan (Parenteral)
  • 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Synovial sarcoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top